This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Malet-Martino, M. Articles by Martino, R. Search for Related Content PubMed PubMed Citation Articles by Malet-Martino, M. Articles by Martino, R.

Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review

Groupe de RMN Biomédicale, Laboratoire des IMRCP, Université Paul Sabatier, Toulouse, France

Correspondence: M. Malet-Martino, Ph.D., Groupe de RMN Biomédicale, Laboratoire des IMRCP (UMR CNRS 5623), Université Paul Sabatier, 118, route de Narbonne, 31062 Toulouse Cédex, France. Telephone: 33-561-556271; Fax: 33-561-557625; e-mail: martino{at}chimie.ups-tlse.fr

Although 5-fluorouracil (5-FU) was first introduced in 1957, it remains an essential part of the treatment of a wide range of solid tumors. 5-FU has antitumor activity against epithelial malignancies arising in the gastrointestinal tract and breast as well as the head and neck, with single-agent response rates of only 10%-30%. Although 5-FU is still the most widely prescribed agent for the treatment of colorectal cancer, less than one-third of patients achieve objective responses. Recent research has focused on the biomodulation of 5-FU to improve the cytotoxicity and therapeutic effectiveness of this drug in the treatment of advanced disease. As all the anticancer agents, 5-FU leads to several toxicities. The toxicity profile of 5-FU is schedule dependent. Myelotoxicity is the major toxic effect in patients receiving bolus doses. Hand-foot syndrome (palmar-plantar erythrodysesthesia), stomatitis, and neuro- and cardiotoxicities are associated with continuous infusions. Other adverse effects associated with both bolus-dose and continuous-infusion regimens include nausea and vomiting, diarrhea, alopecia, and dermatitis. All these reasons explain the need for more effective and less toxic fluoropyrimidines.

In the first part of this review, we briefly present the metabolic pathways of 5-FU responsible for the efficacy and toxicity of this drug. This knowledge is also necessary to understand the target(s) of biomodulation.

The second part is devoted to a review of the literature on three recent prodrugs of 5-FU, i.e., capecitabine, UFT (ftorafur [FTO] plus uracil), and S-1 (FTO plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate). The pharmacological principles that have influenced the development of these new drugs and our current knowledge of the clinical pharmacology of these new agents, focusing on antitumor activity and toxicity, are presented.

The literature was analyzed until March 2002. This review is intended to be as exhaustive as possible since it was conceived as a work tool for readers wanting to go further.

Key Words. Xeloda^® • Orzel^TM • TS-1 • Toxicity • Phase I, II, III trials

This article has been cited by other articles:

				W. Koizumi, N. Boku, K. Yamaguchi, Y. Miyata, A. Sawaki, T. Kato, Y. Toh, I. Hyodo, T. Nishina, T. Furuhata, et al. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer Ann. Onc., October 14, 2009; (2009) mdp371v1. [Abstract] [Full Text] [PDF]

				M. K. Kim, K. H. Lee, B. I. Jang, T. N. Kim, J. R. Eun, S. H. Bae, H. M. Ryoo, S. A. Lee, and M. S. Hyun S-1 and Gemcitabine as an Outpatient-based Regimen in Patients with Advanced or Metastatic Pancreatic Cancer Jpn. J. Clin. Oncol., January 1, 2009; 39(1): 49 - 53. [Abstract] [Full Text] [PDF]

				H.-Y. Zhao, A. Ooyama, M. Yamamoto, R. Ikeda, M. Haraguchi, S. Tabata, T. Furukawa, X.-F. Che, S. Zhang, T. Oka, et al. Molecular Basis for the Induction of an Angiogenesis Inhibitor, Thrombospondin-1, by 5-Fluorouracil Cancer Res., September 1, 2008; 68(17): 7035 - 7041. [Abstract] [Full Text] [PDF]

				J. L. Yen-Revollo, R. M. Goldberg, and H. L. McLeod Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines? Clin. Cancer Res., January 1, 2008; 14(1): 8 - 13. [Abstract] [Full Text] [PDF]

				M. M.Y. Tin, C.-H. Cho, K. Chan, A. E. James, and J. K.S. Ko Astragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft Carcinogenesis, June 1, 2007; 28(6): 1347 - 1355. [Abstract] [Full Text] [PDF]

				D. J. Krosky, M. A. Bianchet, L. Seiple, S. Chung, L. M. Amzel, and J. T. Stivers Mimicking damaged DNA with a small molecule inhibitor of human UNG2 Nucleic Acids Res., November 6, 2006; 34(20): 5872 - 5879. [Abstract] [Full Text] [PDF]

				L. Seiple, P. Jaruga, M. Dizdaroglu, and J. T. Stivers Linking uracil base excision repair and 5-fluorouracil toxicity in yeast Nucleic Acids Res., January 10, 2006; 34(1): 140 - 151. [Abstract] [Full Text] [PDF]

				T. A. Rich, R. C. Shepard, and S. T. Mosley Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232. [Abstract] [Full Text] [PDF]